Precigen Inc.

PGEN | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.28

-$1.66 (-23.92%)

Nov 2, 2026, 12:02 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-23.92%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

45.3

+1.5 pts

Fundamentals Average

Market Sentiment Bullish

Moat None

Sector Rank #388/1028 (Top 38%)

Full Analysis

Key Statistics

Market Data

Market Cap $1.89B

1D Range

4.91 5.36

52W Range

3.10 8.56

Valuation (TTM)

PE -6.09

PB 57.02

EV/EBITDA -17.56

Valuation (NTM)

Forward PE 11.02

Forward PEG 0.05

Price Target $18.00

Cash Flow

FCF Yield -4.7%

SBC Adj. FCF Yield -5.2%

SBC Impact -11.3%

Margins

Gross Margin 89.6%

Operating Margin -46.1%

FCF Margin -135.1%

Growth (CAGR)

Revenue 3Y | 5Y 57.1% | 11.3%

Dil EPS 3Y | 5Y -43.8% | -37.0%

FCF 3Y | 5Y -21.6% | -11.7%

Returns

ROA -92.6%

ROE -498.3%

ROIC -27.8%

Financial Health

Net Debt

$55.67M

Current Ratio 4.58

Interest Coverage -4.06

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineer...

Sector Healthcare

Industry Biotechnology

Employees 160

IPO Date Aug 8, 2013

Website www.precigen.com

Fiscal Year January - December

Full Company Profile

Latest News

4 days ago · prnewswire.com

Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4

GERMANTOWN, Md., Oct. 28, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026.

28 days ago · zacks.com

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

1 month ago · zacks.com

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

1 month ago · zacks.com

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

1 month ago · seekingalpha.com

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.

1 month ago · zacks.com

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

1 month ago · prnewswire.com

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.